Brind.

MiNK Therapeutics saw William Blair downgrade shares after reporting that agenT-797 was used in a Phase I cancer trial combined with Opdivo.

1 report, 1 independent Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MiNK Therapeutics saw William Blair downgrade shares after reporting that agenT-797 was used in a Phase I cancer trial combined with Opdivo.

Who's involved

What this event is mainly about
MiNK Therapeutics (United States)William P. Blair

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Investing.comMiNK Therapeutics stock falls after William Blair downgrade Investing.com -- MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downg